SCHEMBL22716360

SCHEMBL22716360

O=C(O)CCNCC(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.36
EGLN1 Q9GZT9 3/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
ECE1 P42892 1/20 0.35
KDM4E B2RXH2 3/20 0.34
KDM5C P41229 3/20 0.34
PHF8 Q9UPP1 3/20 0.34
KDM2A Q9Y2K7 3/20 0.34
KDM6B O15054 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC22A6 Q4U2R8 1/20 0.33
PRMT1 Q99873 1/20 0.32
FOLH1 Q04609 1/20 0.32
TSHR P16473 2/20 0.32
NFKB1 P19838 1/20 0.32
PMP22 Q01453 1/20 0.32
KMT2A Q03164 1/20 0.32
SIRT5 Q9NXA8 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28818283 0.86 LMNA (0.42) LMNASLC22A6PRMT1TSHRNFKB1
SCHEMBL15114220 0.82 NAALAD2 (0.35) LMNAEGLN1ALKBH5SUCNR1ECE1
SCHEMBL345581 0.80 EGLN1 (0.33) LMNAEGLN1ALKBH5SUCNR1KDM4E
SCHEMBL15114183 0.79 FFAR3 (0.36) ECE1SLC22A6TSHRKMT2APOLB
SCHEMBL15542883 0.78 LMNA (0.38) LMNAEGLN1ALKBH5SUCNR1ECE1
Hydrochloric Acid SCHEMBL16057049 0.78 EGLN1 (0.32) LMNAEGLN1ALKBH5SUCNR1KDM4E
SCHEMBL15197024 0.76 EGLN1 (0.39) LMNAEGLN1ALKBH5SUCNR1ECE1
SCHEMBL109879 0.76 LMNA (0.53) LMNAEGLN1ALKBH5SUCNR1ECE1
SCHEMBL25076095 0.76 TSHR (0.48) LMNAKDM4ESMN1; SMN2TSHRKMT2A
SCHEMBL15114184 0.76 BBOX1 (0.32) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-06-20 US disclosed
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 US disclosed
US-20230080834-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 US disclosed
US-11254673-B2 Small molecule inhibitors of NF-κB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2022-02-22 US disclosed
US-20210300918-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 US disclosed
WO-2020239999-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2020-12-03 WO disclosed
CN-104662015-A Complement pathway modulators and uses thereof NOVARTIS AG 2015-05-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300918-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB LMNA 2532/4885EGLN1 1357/4885ALKBH5 2363/4885
US-20230080834-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB LMNA 2532/4885EGLN1 1357/4885ALKBH5 2363/4885
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase NFKBIA, IKBKB, NFRKB LMNA 2532/4885EGLN1 1357/4885ALKBH5 2363/4885
US-11254673-B2 Small molecule inhibitors of NF-κB inducing kinase NFKBIA, IKBKB, CHUK LMNA 2984/4885EGLN1 1381/4885ALKBH5 2679/4885
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, IKBKE LMNA 2913/4885EGLN1 1258/4885ALKBH5 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.